Table 3.
Outcomes, Costs, and Cost Effectiveness for the Two Cervical Cancer Screening Strategies
| Ages 30–70 years | |||
|---|---|---|---|
| Outcome | Co-testing | HPV primary | Net differencea |
| ICC cases per 10,000 | 57.61 | 79.02 | −21.41 |
| ICC deaths per 10,000 | 23.06 | 43.47 | −20.41 |
| Lifetime QALYsb | 23.0084 | 22.9861 | 0.0223 |
| Screening costs (USD) | $1,319 | $1,129 | $189 |
| Treatment costs (USD) | $1,007 | $1,236 | −$228 |
| Total costs (USD) | $2,326 | $2,365 | −$39 |
| ICERc (USD) | −$1,725 (co-testing dominant) | ||
a
Net difference = Co-testing − HPV primary.
b
QALYs reported as per woman screened.
c
Incremental cost-effectiveness ratio (ICER) = ΔCost / ΔQALY.